Bifidobacterium bifidum OLB6378 (OLB6378) was selected as a strain that enhances the production of secretory immunoglobulin A (IgA) in vitro. This ability of non-live OLB6378 has been shown by a clinical trial in preterm infants. In the present study, we examined whether non-live OLB6378 also enhances the production of secretory IgA, even in full-term infants. One hundred full-term infants were allocated to receive formula with (BbF group, 49 infants) or without non-live OLB6378 (PF group, 51 infants). Breastfeeding was prioritised, so infant formula was used for infants with breastfeeding difficulties. The intervention was initiated by five days of age. The faecal IgA concentration and OLB6378 level were determined at one, two, four, and eight weeks of age.Faecal IgA in the BbF group (1.04 ± 0.47 mg/g of faeces, n = 45) was significantly higher than that in the PF group (0.85 ± 0.42 mg/g of faeces, n = 49) at four weeks of age (p = 0.047). OLB6378 was not detected in faeces at any age. This indicated that production of secretory IgA in full-term infants may also be enhanced by non-live OLB6378 intake.
IntroductionNon-live Bifidobacterium is a safer and more convenient food material than live Bifidobacterium. Moreover, non-live Bifidobacterium cells stimulate the gut immune system in vitro and in vivo [1,2]. However, those effects have not been studied sufficiently in a clinical setting, especially in infants. We selected Bifidobacterium bifidum OLB6378 (OLB6378), which enhances the production of secretory immunoglobulin A (IgA) [3], and confirmed the effect of non-live OLB6378 on enhancement of faecal IgA in low-birth-weight infants [4]. From the standpoint of trying to extend the versatility of non-live OLB6378, we hypothesised that non-live OLB6378 enhances the production of secretory IgA, even in full-term infants.However, the effect observed in low-birth-weight infants may not be observed in full-term infants. Preterm infants have lower body weights, heights, head circumferences, muscle and fat cross-sectional areas, and bone mineral densities than term-born infants [5]. With regard to nutrient digestion and absorption, premature infants do not have levels of intestinal lactase activity and gastric protein digestion capacities comparable to those of mature infants [6][7][8]. They also have immature immune systems and higher levels of intestinal permeability than term infants [9, 10]. Moreover, low birth weight is negatively associated with exclusive breastfeeding [11]. Given these differences between preterm and full-term infants, we considered that the effects of non-live OLB6378 should be demonstrated again in full-term infants.As a pilot study, we evaluated the effects of non-live OLB6378 administration on the enhancement of faecal IgA in full-term infants in this study.
Materials and Methods
Study Design and Ethical ApprovalThis was a double-blind, randomised, placebo-controlled study conducted among 100 newborn infants and their mothers. The protocol was approved by the Ethics Committee of Chiba Univers...